Gastric Cancer Complicated With Bleedin… | Clinical Trial

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients older than 18 years;
A histologically confirmed diagnosis of advanced or metastatic gastric cancer;
The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI);
No history of gastrectomy before systematic therapy.

Exclusion criteria

Incompletable clinical data;
Siewert I type esophagus cancer.

Treatment and study plan

systematic therapy

Drug

All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.

Other names: chemotherapy, targeted therapy or immune checkpoint inhibitor

Primary outcomes

Overall survival (OS)

Time frame: from date of the first cycle of systematic therapy to death from any cause，assessed up to 120 months

OS was defined as the time from the first cycle of systematic therapy to death from any cause.

Study contacts

Contact information is provided by the study sponsor or research team.

Yanhong Yao

CONTACT

[email protected]

+86 010-82265857

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Official study title

Retrospective Study on Anti-cancer Therapy for Gastric Cancer Patients Complicated With Bleeding

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Jul 26, 2024
Registry last updated: Jul 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting